Astellas Pharma Inc.
OTC: ALPMY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Naoki Okamura
- Employees
- 14,754
- Headquarters
- Tokyo, Japan
- IPO year
- 2009
- Market cap
- $24.1B
- Website
- https://www.astellas.com
Loading ALPMY…
Loading profile data…Frequently asked questions about ALPMY
What does Astellas Pharma Inc. (ALPMY) do?
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. The company's diverse pipeline and marketed portfolio address critical unmet medical needs across various therapeutic areas. In oncology, Astella...
Where does ALPMY trade?
Astellas Pharma Inc. (ALPMY) trades on the Other OTC.
What sector is ALPMY in?
Astellas Pharma Inc. (ALPMY) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Astellas Pharma Inc.?
Naoki Okamura is the chief executive officer of Astellas Pharma Inc. (ALPMY).
Where is Astellas Pharma Inc. headquartered?
Astellas Pharma Inc. is headquartered in Japan.
Does ALPMY pay a dividend?
Yes — Astellas Pharma Inc. (ALPMY) paid a trailing twelve-month dividend of USD 0.46 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ALPMY go public?
Astellas Pharma Inc. (ALPMY) completed its initial public offering in 2009.
Is ALPMY an ADR?
Yes — ALPMY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Astellas Pharma Inc. reporting and dividends follow the underlying issuer.